ARTICLE | Clinical News
Lyxumia lixisenatide: Phase IIIb data
August 10, 2015 7:00 AM UTC
The open-label, international Phase IIIb GetGoal Duo-2 trial in 894 Type II diabetics showed that once-daily subcutaneous Lyxumia plus Lantus insulin glargine met the co-primary endpoints of non-infe...